Literature DB >> 20656063

Sotalol-induced torsades de pointes precipitated during treatment with oseltamivir for H1N1 influenza.

Quinn Wells1, Bradley Hardin, Satish R Raj, Dawood Darbar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20656063      PMCID： PMC2946414          DOI： 10.1016/j.hrthm.2010.07.025

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN： 1547-5271            Impact factor:   6.343


× No keyword cloud information.
  7 in total

Review 1.  Drug-induced prolongation of the QT interval.

Authors:  Dan M Roden
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

2.  Approaches to sudden death from coronary heart disease.

Authors:  B Lown; M Wolf
Journal:  Circulation       Date:  1971-07       Impact factor: 29.690

Review 3.  Clinical safety profile of sotalol in patients with arrhythmias.

Authors:  L F Soyka; C Wirtz; R B Spangenberg
Journal:  Am J Cardiol       Date:  1990-01-02       Impact factor: 2.778

4.  The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.

Authors:  George Hill; Tomas Cihlar; Charles Oo; Edmund S Ho; Ken Prior; Hugh Wiltshire; Jo Barrett; Baulian Liu; Penny Ward
Journal:  Drug Metab Dispos       Date:  2002-01       Impact factor: 3.922

5.  Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial.

Authors:  L Køber; P E Bloch Thomsen; M Møller; C Torp-Pedersen; J Carlsen; E Sandøe; K Egstrup; E Agner; J Videbaek; B Marchant; A J Camm
Journal:  Lancet       Date:  2000-12-16       Impact factor: 79.321

6.  Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.

Authors:  C Torp-Pedersen; M Møller; P E Bloch-Thomsen; L Køber; E Sandøe; K Egstrup; E Agner; J Carlsen; J Videbaek; B Marchant; A J Camm
Journal:  N Engl J Med       Date:  1999-09-16       Impact factor: 91.245

Review 7.  Safety and pharmacology of oseltamivir in clinical use.

Authors:  Regina Dutkowski; Bharat Thakrar; Enrico Froehlich; Pia Suter; Charles Oo; Penny Ward
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606
  7 in total
  2 in total

1.  The anti-influenza drug oseltamivir reduces atrial fibrillation in an experimental whole-heart model.

Authors:  Gerrit Frommeyer; André Mittelstedt; Julian Wolfes; Christian Ellermann; Simon Kochhäuser; Patrick Leitz; Dirk G Dechering; Lars Eckardt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-08-06       Impact factor: 3.000

Review 2.  Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.

Authors:  James R Smith; Craig R Rayner; Barbara Donner; Martina Wollenhaupt; Klaus Klumpp; Regina Dutkowski
Journal:  Adv Ther       Date:  2011-11-01       Impact factor: 3.845
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.